Catatonic symptoms appearing before autonomic symptoms help distinguish neuroleptic malignant syndrome from malignant catatonia

Internal Medicine

Volumn 55, Issue 19, 2016, Pages 2893-2897

  Komatsu, Takayuki ^a   Nomura, Tomohisa ^a   Takami, Hiroki ^a   Sakamoto, So ^a   Mizuno, Keiko ^a   Sekii, Hajime ^a   Hatta, Kotaro ^a   Sugita, Manabu ^a  

^a JUNTENDO UNIVERSITY NERIMA HOSPITAL   (Japan)

Author keywords

Malignant catatonia; Matatonic symptoms; Neuroleptic malignant syndrome

Indexed keywords

4 AMINOBUTYRIC ACID; ACICLOVIR; ARIPIPRAZOLE; ASPARTATE AMINOTRANSFERASE; BENZODIAZEPINE; CEFTRIAXONE; CREATINE KINASE; CREATININE; DANTROLENE; FIBRIN; FIBRINOGEN; LACTATE DEHYDROGENASE; LORAZEPAM; SODIUM; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; NEUROLEPTIC AGENT;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BLOOD GAS ANALYSIS; CASE REPORT; CATALEPSY; CATATONIA; CEREBROSPINAL FLUID; COMPUTER ASSISTED TOMOGRAPHY; CONSCIOUSNESS DISORDER; DEEP VEIN THROMBOSIS; DIAPHORESIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; FEMALE; FEVER; GLASGOW COMA SCALE; HUMAN; HYPERNATREMIA; HYPERTHERMIA; LACTATE BLOOD LEVEL; LEUKOCYTOSIS; LIMB TREMOR; LUNG EMBOLISM; MALIGNANT CATATONIA; MUSCLE RIGIDITY; MUTISM; NUCLEAR MAGNETIC RESONANCE IMAGING; SCHIZOPHRENIA; STUPOR; TACHYCARDIA; DIFFERENTIAL DIAGNOSIS; NEUROLEPTIC MALIGNANT SYNDROME; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY;

ADULT; ANTIPSYCHOTIC AGENTS; CATATONIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; GABA MODULATORS; HUMANS; LORAZEPAM; NEUROLEPTIC MALIGNANT SYNDROME; RETROSPECTIVE STUDIES; SCHIZOPHRENIA;

EID: 84989322207     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.55.6613     Document Type: Article

References (20)

1. Walter JA, Jordi SM. Catatonia in the emergency department. Emerg Med J 29: 863-867, 2012.
2. Gelenberg AJ. The catatonic syndrome. Lancet 1: 1339-1341, 1976.
3. Huang TL, Ree SC, Huang YC, Liu HY, Yang YY. Catatonic features: differential diagnosis and treatments at an emergency unit. Psychiatry Clin Neurosci 53: 63-66, 1999.
4. Barnes MP, Saunders M, Walls TJ, Saunders I, Kirk CA. The syndrome of Karl Ludwig Kahlbaum. J Neurol Neurosurg Psychiatry 49: 991-996, 1986.
5. Rosebush PI, Hildebrand AM, Furlong BG, Mazurek MF. Catatonic syndrome in a general psychiatric inpatients population: frequency, clinical presentation, and response to lorazepam. J Clin Psychiatry 51: 357-362, 1990.
6. Carroll M, Taylor Am. Catatonia: a separate category for DSM-IV? Integr Psychiatry 7: 2-10, 1991.
7. American Psychiatric Association. Diagnostic and Statistical Manual of mental disorders. Fourth Edition (Text revision). American Psychiatric Association, Washington DC, 2000.
8. American Psychiatric Association. Diagnostic and Statistical Manual of mental disorders. Fifth Edition. American Psychiatric Association, Arlington, 2013.
9. Lang FU, Lang S, Becker T, Jäger M. Neuroleptic malignant syndrome or catatonia? Trying to solve the catatonic dilemma. Psy-chopharmacology 232: 1-5, 2015.
10. Tseng PT, Chang YC, Chang CH, et al. Atypical neuroleptic malignant syndrome in patients treated with aripiprazole and cloza-pine: a case-series study and short review. Int J Psyciatry Med 49: 35-43, 2015.
11. Margeti B, Aukst-Margeti B. Neuroleptic malignant syndrome and its controversies. Pharmacoepidemiol Drug Saf 19: 429-435, 2010.
12. Bhanushali MJ, Tuite PJ. The evaluation and management of patients with neuroleptic malignant syndrome. Neurol Clin N Am 22: 389-411, 2004.
13. Adnet P, Lestavel P, Krivosic-Horber. Neuroleptic malignant syndrome. Br J Anaesth 85: 129-135, 2000.
14. Belvederi Murr M, Guaglianone A, Bugliani M, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs R D 15: 45-62, 2015.
15. Ohno Y, shimizu S, Tokudome K. Pathophysiological roles of serotonergic system in regulating extrapyramidal motor functions. Biol Pharm Bull 36: 1396-1400, 2013.
16. Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psyciatry 156: 169-180, 1999.
17. Odagaki Y. Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics? Curr Drug Saf 4: 84-93, 2009.
18. Northoff G. What catatonia can tell us about “top-down modula- tion”: a neuropsychiatric hypothesis. Behav Brain Sci 25: 555-577, discussion 578-604, 2002.
19. Fink M, Taylor MA. Catatonia: A Clinician’s Guide to Diagnosis and Treatment. Cambridge University Press, Cambridge, 2003.
20. Dessens FM, van Paassen J, van Westerloo DJ, et al. Electrocon-vulsive therapy in the intensive care unit for the treatment of catatonia: a case series and review of the literature. Gen Hosp Psychiatry 38: 37-41, 2016.